# Study to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected Individuals

> **NCT02616874** · PHASE1 · COMPLETED · sponsor: **IrsiCaixa** · enrollment: 15 (actual)

## Conditions studied

- HIV

## Interventions

- **DRUG:** MVA.HIVconsv vaccine
- **DRUG:** Romidepsin

## Key facts

- **NCT ID:** NCT02616874
- **Lead sponsor:** IrsiCaixa
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02
- **Primary completion:** 2016-09
- **Final completion:** 2017-10-30
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2024-05-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02616874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02616874, "Study to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected Individuals". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02616874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*